Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Featured Article from MarketBeat.com Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we're still in one of the best times in history to build wealth—especially if you think long term and stick to time-tested principles. Green says the pullback isn't as severe as it may feel. "Just last Wednesday, the Dow hit an all-time high," he noted, explaining that recent selling pressure stems more from valuation concerns and interest-rate uncertainty than any fundamental breakdown. Why the Market Pulled Back In 1999, Sutter Hill Ventures made a bold bet on Nvidia before anyone had heard of it. Now, they're going all-in on Nvidia's hush-hush partner that's powering their new Blackwell chip. Discover the little-known company that's attracting massive investments from the visionaries behind Nvidia's 100,000% rise. Unlock the hidden key to AI's future. Green attributes the dip to two core concerns. First, investors are beginning to question elevated tech and AI valuations, particularly as earnings season brings those expectations into focus. Second, inflation data and slower hiring have cooled hopes that the Fed will cut rates in December. With the central bank taking a "data-dependent" stance, markets are less certain that relief is coming this year. Why Selling Now Might Be the Wrong Move Rather than trying to predict next week's moves, Green urges investors to zoom out. He calls himself "a long-term optimist," and notes that, historically, the market's trend is upward. Traders may want to be cautious in the short term, but for long-term investors these dips often create opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One of the most reliable indicators in times like these is insider buying. Green suggests paying attention when officers and directors—people with access to non-public company information—are investing in their own companies. He recommends tracking insider trading activity to see which stocks corporate executives are buying, not just selling. While insiders aren't always right, their actions can be a useful signal when markets are in flux. A Biotech Breakout to Watch: GRAIL One sector Green is focusing on now is biotech, where artificial intelligence is accelerating drug development and lowering costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL has developed the Galleri Test, which can detect more than 50 types of cancer from a single blood draw. Green has used the test himself and calls it "a good feeling" to know you're clear of many deadly diseases—especially cancers like pancreatic that are often detected late. With FDA fast-track status and potential insurance reimbursement on the horizon, Green views GRAIL's roughly $3 billion market cap as an early stage for the company's upside. The Biotech Risk—and Big Pharma's Appetite Biotech investing carries risk: most drugs never clear all three phases of clinical trials. Still, larger pharmaceutical firms such as Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) actively acquire promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as a recent example: the company invested in a private prostate cancer drug before it received FDA approval, underscoring how aggressive Big Pharma can be when clinical data looks promising. He also notes that healthcare is relatively recession-proof. Whether the economy is growing or contracting, people continue to seek treatment. For investors seeking stability during volatility, sectors like healthcare, utilities, consumer staples, and food companies often offer steady demand and less drama than high-flying AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green argues the American Dream remains attainable. He wrote The American Dream to challenge the narrative that it's out of reach, noting he was surprised to see polls showing nearly 70% of Americans believe it's no longer attainable. His point: with low-cost investment tools, commission-free trading, and abundant information, building wealth is more accessible than ever. The real challenge is knowing what to do—and having the discipline to do it. He offers a simple example: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—if you save consistently and let the money compound. Creative Solutions for Today's Housing Market Housing can feel out of reach, but Green emphasizes there are creative paths in. Mortgage rates have doubled and prices are up about 50% since the pandemic, yet opportunities remain. He shares a personal example of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a method sometimes called a "contract for deed." It may not get you the perfect home immediately, but it can help you start building equity sooner. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it's tracking insider moves, exploring high-upside areas like biotech, or simply committing to steady savings, Green's message is consistent: the American Dream is still within reach. Keep your eyes on the prize—and take the next right step.
| 
